BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 29737430)

  • 1. hIL-15-gene modified human natural killer cells (NKL-IL15) exhibit anti-human leukemia functions.
    Jiang W; Zhang C; Tian Z; Zhang J
    J Cancer Res Clin Oncol; 2018 Jul; 144(7):1279-1288. PubMed ID: 29737430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
    Jiang W; Zhang C; Tian Z; Zhang J
    Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. hIFN-α gene modification augments human natural killer cell line anti-human hepatocellular carcinoma function.
    Jiang W; Zhang C; Tian Z; Zhang J
    Gene Ther; 2013 Nov; 20(11):1062-9. PubMed ID: 23759701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional characterization of interleukin-15 gene transduction into the human natural killer cell line NKL.
    Jiang W; Zhang J; Tian Z
    Cytotherapy; 2008; 10(3):265-74. PubMed ID: 18418772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15.
    Imamura M; Shook D; Kamiya T; Shimasaki N; Chai SM; Coustan-Smith E; Imai C; Campana D
    Blood; 2014 Aug; 124(7):1081-8. PubMed ID: 25006133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy.
    Ayello J; Hochberg J; Flower A; Chu Y; Baxi LV; Quish W; van de Ven C; Cairo MS
    Exp Hematol; 2017 Feb; 46():38-47. PubMed ID: 27765614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment, characterization, and successful adaptive therapy against human tumors of NKG cell, a new human NK cell line.
    Cheng M; Ma J; Chen Y; Zhang J; Zhao W; Zhang J; Wei H; Ling B; Sun R; Tian Z
    Cell Transplant; 2011; 20(11-12):1731-46. PubMed ID: 21669033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of interleukin-15 gene-modified human natural killer cells: implications for adoptive cellular immunotherapy.
    Zhang J; Sun R; Wei H; Zhang J; Tian Z
    Haematologica; 2004 Mar; 89(3):338-47. PubMed ID: 15020274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antileukemia activity of a natural killer cell line against human leukemias.
    Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
    Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent Cytolytic Activity and Specific IL15 Delivery in a Second-Generation Trispecific Killer Engager.
    Felices M; Lenvik TR; Kodal B; Lenvik AJ; Hinderlie P; Bendzick LE; Schirm DK; Kaminski MF; McElmurry RT; Geller MA; Eckfeldt CE; Vallera DA; Miller JS
    Cancer Immunol Res; 2020 Sep; 8(9):1139-1149. PubMed ID: 32661096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice.
    Siegler U; Kalberer CP; Nowbakht P; Sendelov S; Meyer-Monard S; Wodnar-Filipowicz A
    Leukemia; 2005 Dec; 19(12):2215-22. PubMed ID: 16224486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation and preclinical characterization of an NKp80-Fc fusion protein for redirected cytolysis of natural killer (NK) cells against leukemia.
    Deng G; Zheng X; Zhou J; Wei H; Tian Z; Sun R
    J Biol Chem; 2015 Sep; 290(37):22474-84. PubMed ID: 26198633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor.
    Sahm C; Schönfeld K; Wels WS
    Cancer Immunol Immunother; 2012 Sep; 61(9):1451-61. PubMed ID: 22310931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity.
    Van den Bergh J; Willemen Y; Lion E; Van Acker H; De Reu H; Anguille S; Goossens H; Berneman Z; Van Tendeloo V; Smits E
    Oncotarget; 2015 Dec; 6(42):44123-33. PubMed ID: 26675759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rescuing lymphocytes from HLA-G immunosuppressive effects mediated by the tumor microenvironment.
    Wu D; Kuiaste I; Moreau P; Carosella E; Yotnda P
    Oncotarget; 2015 Nov; 6(35):37385-97. PubMed ID: 26460949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Oncolytic Virus Expressing IL15/IL15Rα Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma.
    Ma R; Lu T; Li Z; Teng KY; Mansour AG; Yu M; Tian L; Xu B; Ma S; Zhang J; Barr T; Peng Y; Caligiuri MA; Yu J
    Cancer Res; 2021 Jul; 81(13):3635-3648. PubMed ID: 34006525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity.
    Cichocki F; Valamehr B; Bjordahl R; Zhang B; Rezner B; Rogers P; Gaidarova S; Moreno S; Tuininga K; Dougherty P; McCullar V; Howard P; Sarhan D; Taras E; Schlums H; Abbot S; Shoemaker D; Bryceson YT; Blazar BR; Wolchko S; Cooley S; Miller JS
    Cancer Res; 2017 Oct; 77(20):5664-5675. PubMed ID: 28790065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapeutic effects of cytokine-induced killer cells combined with CCL21/IL15 armed oncolytic adenovirus in TERT-positive tumor cells.
    Ye JF; Lin YQ; Yu XH; Liu MY; Li Y
    Int Immunopharmacol; 2016 Sep; 38():460-7. PubMed ID: 27380620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of NK and CD8+T cells with CCL20/IL15-armed oncolytic adenoviruses enhances the growth suppression of TERT-positive tumor cells.
    Ye JF; Qi WX; Liu MY; Li Y
    Cell Immunol; 2017 Aug; 318():35-41. PubMed ID: 28651743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth.
    Oelsner S; Waldmann A; Billmeier A; Röder J; Lindner A; Ullrich E; Marschalek R; Dotti G; Jung G; Große-Hovest L; Oberoi P; Bader P; Wels WS
    Int J Cancer; 2019 Oct; 145(7):1935-1945. PubMed ID: 30860598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.